- Open Access
Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus
© Czarnota et al. 2016
- Received: 10 October 2015
- Accepted: 31 March 2016
- Published: 13 April 2016
Hepatitis C virus (HCV) infection is a major health problem worldwide, affecting an estimated 2–3 % of human population. An HCV vaccine, however, remains unavailable. High viral diversity poses a challenge in developing a vaccine capable of eliciting a broad neutralizing antibody response against all HCV genotypes. The small surface antigen (sHBsAg) of hepatitis B virus (HBV) has the ability to form highly immunogenic subviral particles which are currently used as an efficient anti-HBV vaccine. It also represents an attractive antigen carrier for the delivery of foreign sequences. In the present study, we propose a bivalent vaccine candidate based on novel chimeric particles in which highly conserved epitope of HCV E2 glycoprotein (residues 412–425) was inserted into the hydrophilic loop of sHBsAg.
The expression of chimeric protein was performed in an unconventional, Leishmania tarentolae expression system resulting in an assembly of particles which retained immunogenicity of both HCV epitope and sHBsAg protein. Direct transmission electron microscopy observation and immunogold staining confirmed the formation of spherical particles approximately 22 nm in diameter, and proper foreign epitope exposition. Furthermore, the sera of mice immunized with chimeric particles proved reactive not only to purified yeast-derived sHBsAg proteins but also HCV E2 412–425 synthetic peptide. Most importantly, they were also able to cross-react with E1E2 complexes from different HCV genotypes.
For the first time, we confirmed successful assembly of chimeric sHBsAg virus-like particles (VLPs) in the L. tarentolae expression system which has the potential to produce high-yields of properly N-glycosylated mammalian proteins. We also proved that chimeric Leishmania-derived VLPs are highly immunogenic and able to elicit cross-reactive antibody response against HCV. This approach may prove useful in the development of a bivalent prophylactic vaccine against HBV and HCV and opens up a new and low-cost opportunity for the production of chimeric sHBsAg VLPs requiring N-glycosylation process for their proper functionality and immunogenicity.
- Hepatitis C virus (HCV)
- HBV small surface antigen (sHBsAg)
- Leishmania tarentolae
Although recent advances in hepatitis C treatment give reasons for optimism, a prophylactic vaccine for hepatitis C virus (HCV) remains an elusive goal. The recently developed direct-acting antiviral drugs (DAAs) have improved the sustained viral response (SVR) rates up to even 99 % for Sofosbuvir/Ledipasvir therapy . Unfortunately, the cost of the DAA therapy is still extremely high . Considering the above, the development of an effective prophylactic vaccine against HCV should be a medical priority. HCV infection affects an estimated 2–3 % of human population and the number is even higher in undeveloped countries, including Egypt with the HCV prevalence of 20 % . Approximately 70–80 % of the infected individuals develop chronic liver disease, which can lead to cirrhosis and liver carcinoma.
HCV is a member of the Flaviviridae family. Its single stranded positive-sense RNA genome codes for both structural and non-structural viral proteins. The HCV nucleocapsid is surrounded by E1E2 envelope glycoproteins embedded in a lipid envelope. E1 and E2 glycoproteins constitute a potential target for the development of a prophylactic HCV vaccine, as they are involved in virus–host interaction, and the antibodies directed against these proteins seem to neutralize HCV . Due to the fact that resolution of HCV infection is mediated not only by a broad and potent T cell response , but also by the neutralizing antibodies (nAbs) raised mainly against HCV E1E2 heterodimer [6, 7], a prophylactic vaccine consisting of adjuvanted recombinant E1E2 heterodimer was proposed. The most advanced approach included immunization with E1E2 complex expressed in Chinese hamster ovary (CHO) cell line. Phase I clinical trials indicated that immunization with glycosylated envelope proteins resulted in potent nAbs and CD 4+ T-cell responses [8, 9].
The major obstacle in the development of a protective immunity against HCV is its high genetic diversity and variability. In recent studies, HBV capsid-like particles (CLPs) were used to present variants of the HCV E2 glycoprotein hyper-variable region 1 (HVR1). HVR1 is one of the most immunogenic regions of glycoprotein E2, but its constant evolution and diversity along HCV genotypes leads to limited cross-reactivity of the elicited antibodies . The region located downstream of HVR1 contains a potent and highly conserved epitope first identified by the mouse monoclonal antibody AP33. The region, spanning residues 412–423 of glycoprotein E2, can elicit broadly nAbs capable of inhibiting HCV, both in vitro and in vivo [11, 12]. Epitope AP33 is highly conserved among over 5500 E2 sequences in the GenBank database and mostly regarded as a linear epitope . These features make 412–423 residues a perfect peptide antigen expressed on various antigen carriers. Moreover, the region is only 13 amino acids long and does not include any additional cysteine residue that could result in formation of non-authentic disulfide bonds and disrupt the carrier structure . In general, peptide vaccines used in isolation are weakly immunogenic and require some carries for delivery . This finds support in a recently published report which shows that monoclonal antibodies (mAbs) generated against a cyclic variant of the AP33 epitope bind poorly to E2 and do not neutralize the virus .
Yeast-derived HBV small surface antigen (sHBsAg) forms particles 22 nm in diameter currently used worldwide as the commercial recombinant hepatitis B vaccine. sHBsAg tertiary structure forms a highly conserved, hydrophilic loop containing the major B-cell epitopes also known as the “a”-determinant [16, 17]. Because of its immunogenic potential, sHBsAg was also applied as an antigen carrier to deliver foreign sequences and induce anti-foreign humoral and cellular responses [13, 18–25].
The present study focused on construction, characterization and immunological studies of novel sHBsAg chimeric particles produced in the L. tarentolae expression system. The system enables production of recombinant proteins with their mammalian-like N-glycosylation pattern. Moreover, L. tarentolae can grow in biofermenters to a high cell density and the recombinant protein production yield can reach several milligrams per liter of culture [26, 27]. Here, we propose a new vaccine candidate based on chimeric particles in which the HCV E2 glycoprotein region (aa 412–425) is inserted within the “a”-determinant loop of sHBsAg. We show that Leishmania-derived HBV/HCV chimeric particles elicit promising titers of cross-reactive antibodies against HCV. These particles also induce both humoral and cellular immune response against HBV, opening a new and low-cost approach to bivalent vaccine development.
Expression and characterization of sHBsAg and 412–425_sHBsAg particles
Immunogenicity of sHBsAg and 412–425_sHBsAg particles
Next, we studied the antibody response of 412–425_sHBsAg particles to 412–425 epitope. Interestingly, sera from the 412–425_sHBsAg group were able to recognize not only the sHBsAg protein (as mentioned above), but also synthetic peptide corresponding to the 412–425 region of HCV E2 glycoprotein. The endpoint titer in peptide ELISA test reached 103. The AP33 standard curve showed that the amount of anti-412–425 epitope antibody in serum corresponded to AP33 antibody concentration of approximately 0.9 mg/mL (Fig. 6c). Furthermore, we decided to test cross-reactivity of the sera from 412–425_sHBsAg immunized mice against E1E2 complex from different HCV genotypes. As expected, the antisera recognized E2 glycoproteins from HCV genotypes 1a, 1b, 2b, 3a, 4, and 6, but failed to recognize E2 derived from genotype five (Fig. 6d). That was due to the fact that genotype five isolate had 4 amino acid changes in region 412–423 in comparison with the sequence used to create 412–425_sHBsAg protein. Such a modification may influence epitope recognition as well as neutralization of the HCV pseudotype particles (HCVpp) . All facts considered, the 412–425_sHBsAg sera were found broadly cross-reactive across the HCV genotypes.
To recapitulate, the immunization studies confirmed that both Leishmania-derived particles are highly immunogenic in mice. Moreover, the 412–425_sHBsAg sera recognized efficiently both the 412–425 peptide and mammalian cell culture-derived E2 protein from different HCV genotypes, as well as yeast-derived sHBsAg proteins.
Despite the discovery of highly effective antiviral agents, 3–4 million new HCV infections every year still represent a major health problem. Therefore, the development of an effective and a low-cost prophylactic vaccine is needed to control global HCV infection. For years, humoral response and nAbs were considered to play a side role in HCV infection process. However, recent studies suggest that nAbs play an active role in HCV spontaneous resolution [6, 7, 31]. During the infection, all known nAbs target epitopes within the HCV envelope glycoproteins E1 and E2, prevailingly the E2 epitopes. The ectodomain of the E2 glycoprotein contains three regions of variability that are targeted by nAbs—HVR1, HVR2, plus the intergenotypic variable region. HVR1 is a 26–28 aa long fragment responsible for interactions with cellular SR-BI receptor . Because of its high immunogenicity, HVR1 was often considered a potential vaccine epitope. However, a recent approach where HVR1 is used as an antigen carried on HBV capsid-like particles showed deficiency in the HCVpp and cell culture HCV (HCVcc) cross-neutralization . Unfortunately, HVR1 is the most variable region of HCV and the high rate of mutation within this region results in poor cross-neutralization across different HCV isolates. It has been reported that HVR1 plays the role of a major epitope decoy that elicits isolate-specific nAbs from which the HCV can easily escape .
It has previously been demonstrated that CD81-binding regions of HCV E2 glycoprotein are highly conserved and represent the main target for the broad range of nAbs [11, 31, 34, 35]. Thus, the intrinsically conserved epitopes able to induce cross-neutralizing antibodies seem to be essential in vaccine development. The recent data suggest that recombinant E1E2 complex is capable of eliciting antibodies that bind the conserved residues overlapping epitopes of many broadly cross-neutralizing antibodies targeting E2-CD81 interaction .
In this study, we decided to design particles carrying broadly-neutralizing 412–425 epitope and insert it into the major antigenic loop of sHBsAg protein. Both sHBsAg (wild-type) and 412–425_sHBsAg (chimeric) proteins were expressed in L. tarentolae cells at similar efficiencies. The fact indicates that epitope insertion did not impair the protein folding. This is consistent with observation from previous study which showed that “a”-determinant of sHBsAg can support 36 amino acids insertions without an impact on the particle expression efficiency . The insertion of 412–425 epitope in “a”-determinant was confirmed by cell lysate ELISA and immunogold labeling of particles with AP33 antibodies. The EM analysis revealed that 412–425_sHBsAg particles were present in the cell lysate and their shape resembled the correctly assembled sHBsAg particles expressed in the mammalian or yeast expression systems [29, 37].
Over the last few years, new vaccination approaches involving VLP-based vaccines have been developed. VLP are effective immunogens and due to their highly organized structure they are able to elicit both the nAbs and T-cell responses . sHBsAg has been shown to self-assemble into highly immunogenic, non-infectious subviral particles, and is used worldwide as a safe, commercial hepatitis B vaccine. The sHBsAg protein was previously expressed in mammalian , baculovirus , E.coli , and yeast systems utilizing P. pastoris [29, 41], S. cerevisiae , H. polymorpha , and Y. lipolytica . The choice of S. cerevisiae yeast for commercial production of sHBsAg was dictated by low cultivation costs and high protein yield. However, unlike in the mammalian expression system, the yeast-derived sHBsAg is not glycosylated, which is a major drawback of the yeast-based systems. Noteworthy, sHBsAg expression in mammalian cells leads to particle secretion [18, 23, 44]. The process significantly simplifies purification of particles from the culture medium. On the other hand, particle secretion was never observed in yeast systems where protein was retained within ER partially assembling into multi-layer lamellar structures. There is no evidence for the presence of the particles within the yeast cells . Importantly, the assembly of L. tarentolae expressed particles was confirmed by electron microscopy, though we never observed any particle secretion into the culture medium. They are possibly retained in ER, just as the yeast-derived virus-like particles (VLPs), and the assembly of the particles probably occurs after the cell lysis in the subsequent down-stream processing.
This report is the first to describe efficient expression of sHBsAg in a eukaryotic protozoan L. tarentolae-based expression system. The L. tarentolae system has recently been used to express immunogenic human papillomavirus (HPV) L1 VLPs  and to produce recombinant proteins with the N-glycosylation pattern similar to the mammalian one, as demonstrated for erythropoietin  and soluble amyloid precursor protein alpha (sAPPalpha) . Region 412–425 of the HCV E2 glycoprotein includes two highly conserved glycosylation sites which have recently been shown to play an important role in epitope recognition by the broadly neutralizing monoclonal antibodies AP33, HCV1 , and HC33.11 . Moreover, it has previously been shown that the structure of oligosaccharides attached to hemagglutinin can play an important role in its immunogenicity . The N-glycosylation pattern of L. tarentolae-derived particles should be further analyzed, although higher mass of the 412–425_sHBsAg protein and the results of deglycosylation with PNGase F suggest the presence of additional N-glycans.
Recently, various strategies of using sHBsAg as the prophylactic HCV vaccine candidates have been investigated. It has been shown that pre-existing immunity to sHBsAg does not impede immune response against foreign epitopes or proteins carried on an sHBsAg particle. This suggests that chimeric HBsAg-based particles can be used in the booster dose strategy in individuals previously vaccinated against HBV [50, 51]. The use of sHBsAg particles as carriers of small HCV epitopes inserted into the antigenic external hydrophilic loop was reported in several studies [23, 24, 52]. Another approach involved the design of chimeric HBV-HCV particles in which the N-terminal transmembrane domain (TMD) of the sHBsAg protein was replaced with the TMD of HCV full-length E1 or E2 proteins . Those chimeric particles expressed in CHO cells elicited strong antibody response against both HBsAg and HCV envelope proteins in immunized rabbits . Moreover, the sera displayed cross-neutralizing activity against HCVpp and HCVcc, although the T-cell response of chimeric particles was not analyzed. Here, we tested the ability of Leishmania-derived particles to elicit a cellular response using an in vitro T cell activation assay. The strongest response occurred against sHBsAg peptide pools one and three. These results are in agreement with other reports suggesting that most T-cell immunodominant epitopes are located outside the “a”-determinant region [54, 55]. It also proves that the location of a foreign epitope does not interfere with cellular response against chimeric VLPs. Not surprisingly, no cellular response was detected when splenocytes were stimulated with 412–425 synthetic peptide (the results not shown). The outcome supports the previous findings, namely that almost no cellular epitopes were present on HCV envelope glycoproteins versus the core or NS proteins [5, 56]. Additionally, we observed a higher cellular response in mice immunized with chimeric 412–425_sHBsAg particles than in those immunized with wild-type particles. An N-glycan structural analysis confirmed that L. tarentolae is able to produce mammalian-like, as well as mannose-terminated N-glycans . Several reports show that mannosylation of particles enhances antigen uptake and processing by the antigen presenting cells [57–59]. Possibly, additional N-glycans present in 412–425_sHBsAg particles are mannose-terminated and may promote a stronger cellular response. Nevertheless, it should be emphasized that no significant differences in the humoral responses were observed.
The antibody response to mammalian and yeast-derived sHBsAg is well documented [37, 60]. In this study, we proved strong immunogenicity of L. tarentolae-derived particles, since the antibody titers in the sera of both analyzed mouse groups reached 5 × 105 (Fig. 6a). The 412–425_sHBsAg sera were able to detect both synthetic peptide (Fig. 6c) and yeast-derived sHBsAg proteins (Fig. 6b). However, immune response against sHBsAg protein was weaker in the 412–425_sHBsAg group of mice than in the sHBsAg wild-type group. This is consistent with the previous findings which described lessening of the anti-sHBsAg immune response in animals immunized with chimeric particles versus those immunized with wild-type particles . It has also been demonstrated that changes within external hydrophilic loop are strongly associated with the sHBsAg protein antigenicity . Furthermore, our findings proved that 412–425_sHBsAg sera were able to recognize not only the synthetic peptide, but also HCV E2 glycoprotein of most virus genotypes, which indicated presence of broadly cross-reactive antibodies (Fig. 6d).
There is abundant evidence clearly demonstrating the importance of the cross-neutralizing antibodies in spontaneous clearance of HCV infection. Promising results have been obtained for adenovirus-based vaccine proved to induce a broad, strong and long-lasting T-cell response in healthy humans . Thus, the development of a prophylactic vaccine can be achieved by combination of antigens which are able to elicit simultaneous T and B cell responses, both crucial for the successful protection against HCV [10, 36, 63].
Since HCV displays high genetic diversity, the ideal prophylactic vaccine should elicit antibodies against the highly conserved viral regions. Our results indicate that chimeric sHBsAg VLPs carrying a highly conserved HCV epitope may elicit cross-reactive antibodies against HCV while preserving anti-sHBsAg “a”-determinant immunogenicity. This approach, combined with a vaccine inducing a strong T-cell response against HCV, may be useful in developing a cost-effective bivalent prophylactic vaccine against the two main hepatotropic human pathogens. Moreover, chimeric sHBsAg particles were successfully expressed in L. tarentolae system, which can be considered an alternative to mammalian cells for large-scale production of N-glycosylated VLPs for pharmaceutical purposes.
Figure 1 summarizes the construction of the 412–425_sHBsAg chimeric gene used in this work. The region of HCV E2 glycoprotein, spanning the 412–425 residues (isolate H77c, GenBank accession no. AF011751) was inserted within HBV subtype adw2 sHBsAg amino acid positions 127P and 128A (GenBank accession no. AF397207.1). The construct was obtained by gene synthesis using L. tarentolae-adapted codon (GeneArt—Thermo Fisher Scientific). The gene coding for sHBsAg was synthetized as mentioned above. Synthetized genes were ligated into BglII—NotI restriction sites in the pLEXSY_I-blecherry3 vector (Jena Bioscience). For HCV E2 glycoprotein expression in human epithelial kidney (HEK) 293 cells, we used plasmids coding for full-length E1E2 derived from HCV genotypes: 1a (isolate H77.20); 1b (UKN1B.12.6); 2a (UKN2A.2.4); 3a (UKN3.1.9); 4 (UKN4.21.16); 5 (UKN5.14.4); and 6 (UKN6.5.8) – kindly provided by J. Ball.
Leishmania tarentolae cultivation and protein expression
HBV small surface antigen and 412–425_sHBsAg proteins were expressed using the inducible LEXSY expression system according to the manufacturer’s instructions (Jena Bioscience). Briefly, the plasmids were transfected into L. tarentolae cells by electroporation. Transfected cells were selected with bleomycin (100 µg/mL) in suspension culture. Subsequently, recombinant cell lines were cultivated in 25 cm2 tissue culture flasks filled with 10 mL of selective medium supplemented with hemin at 26 °C and kept away from light. The T7 promoter driven transcription was induced by adding tetracycline to the final concentration of 15 µg/mL. Cells were grown in 500 mL shake flasks for 72 h, at 26 °C, in agitated culture to the final optical density of 4–5 at 600 nm (OD600).
For immunofluorescence labeling, tetracycline-induced L. tarentolae cells were washed with PBS and fixed in 4 % paraformaldehyde for 30 min at RT. Lysine-coated glass coverslips were covered with fixed cell suspension and left to dry at RT. Next, the cells were permeabilized with 0.2 % Triton X-100 in PBS for 10 min at RT. Subsequently, the coverslips were incubated with primary rabbit anti-HBsAg (Abcam) and mouse anti-E2 AP33 (kindly provided by A. Patel) antibodies diluted to 1:1000 in PBS-BSA buffer [0.5 % (w/v) BSA] for 1 h at RT. The coverslips were then washed with PBS and incubated with Alexa Fluor 633-labeled goat anti-mouse and Alexa Fluor 488-labeled goat anti-rabbit secondary antibodies (1:1000 in PBS-BSA) for 1 h at RT. After washing, the coverslips were mounted onto microscope slides with ProLong Gold antifade reagent.
SDS-PAGE and western blot
Analysis of the particle expression was carried out by SDS-PAGE using 4–12 % gradient Bis–Tris gels in MES SDS running buffer. After electrophoresis, proteins were transferred onto PVDF membrane using electroblotting, and subsequently the membranes were blocked overnight at 4 °C with 3 % nonfat milk in TBST [TBS buffer, 0.1 % (v/v) Tween-20]. Following blocking, membranes were incubated for 1 h at RT with primary anti-HBsAg antibodies diluted in TBST, washed with TBST, and then incubated with goat anti-rabbit secondary AP—conjugated antibodies (Santa Cruz Biotechnology). The results were developed using the BCIP/NBT substrate.
For testing serum cross-reactivity, HEK 293 cells were transfected with plasmids expressing glycoproteins E1E2 derived from different HCV genotypes. 72 h after transfection, cells were washed with PBS buffer and lysed in lysis buffer (PBS buffer, 1 % Triton X-100). The clarified cell lysates were separated using SDS-PAGE and transferred onto PVDF membrane as described above. Following the blocking, the membranes were incubated for 1 h at RT with a mixture of pooled 412–425_sHBsAg sera diluted 1:500, washed with TBST and then incubated with goat anti-mouse secondary HRP—conjugated antibodies (Santa Cruz Biotechnology).
PNGase F treatment
412–425_sHBsAg and sHBsAg cell lysates were boiled for 10 min in denaturing buffer (0.5 % SDS, 40 mM DTT). The samples were divided into two equal portions and incubated for 16 h at 37 °C, with or without PNGase F, according to the manufacturer’s instructions (New England Biolabs). The results were visualized with western blot using anti-HBsAg antibodies as described above.
Cell lysis and ultracentrifugation
Hundred milliliter of tetracycline-induced cell culture was centrifuged at 4 °C, 8000 rpm, for 15 min. The cell pellet was either stored at −20 °C until use or immediately resuspended in 10 mL of ice-cold lysis buffer [PBS buffer, 0.6 % (v/v) Tween-20]. Cells were sonicated and the suspension was clarified by centrifugation at 4 °C, 8000 rpm, for 35 min.; the supernatant was left for 16–24 h at RT for particle formation. Subsequently, the lysate was layered on an OptiPrep (Sigma-Aldrich) gradient formed in ultra-clear tubes [2 mL of 30 % (v/v) OptiPrep, 2 mL 24 % (v/v) OptiPrep, 1.5 mL 18 % (v/v) OptiPrep, 1.5 mL 12 % (v/v) OptiPrep, and 1.5 mL 6 % (v/v) OptiPrep in ultra-clear water] and ultracentrifuged at 27,000 rpm for 16 h at 4 °C. Then, 500 µL fractions were harvested and analyzed by western blot using anti-HBsAg rabbit polyclonal antibodies (Abcam). Purity of the fractions was analyzed by SDS-PAGE with Coomassie R-250 staining. sHBsAg positive fractions of the highest purity were pooled, and OptiPrep buffer was replaced with PBS using Amicon Ultra 100 K centrifugal units (Merck Millipore). The thus prepared samples were used for further analysis.
Cell lysate ELISA
ELISA 96-well plates were left for coating with cell lysates diluted in PBS for 16 h at 4 °C. Each well was then blocked with 3 % (w/v) BSA in PBST [PBS buffer, 0.05 % (v/v) Tween-20] for 2 h at RT. Primary mouse monoclonal AP33 and rabbit polyclonal anti-HBsAg (Acris Antibodies) were diluted in PBST with 0.3 % (w/v) BSA and added to the wells. After the washing, primary antibodies were detected with the goat anti-mouse or goat anti-rabbit secondary HRP-conjugated antibodies (Santa Cruz Biotechnology). The reaction with TMB substrate was stopped with 0.5 M H2SO4 and signal intensity at 450 nm was measured using plate reader (TECAN).
Groups of 6 BALB/c female mice, 6–8 weeks of age, were immunized subcutaneously with squalene-based oil-in-water nanoemulsion adjuvant (Addavax, InvivoGen). The mice were immunized with 15 µg of protein on day 0, and with 10 µg on days: 14 and 28. The mice used as negative controls were immunized with PBS-adjuvant mixture alone. All experiments on animals were conducted by an accredited company (Tri-City Academic Laboratory Animal Centre, Medical University of Gdańsk), in accordance with the current guidelines for animal experimentation. The protocols were approved by the Committee on the Ethics of Animal Experiments of the Medical University of Gdańsk (Permit Number: 46/2012). All surgery was performed under isoflurane anesthesia, and all efforts were made to minimize suffering.
Analysis of antibody response
Mouse sera were collected on day 42 and pooled into two groups. Antibody response was measured by direct solid-phase ELISA using immunogens 10 µg/mL, 412–425 synthetic peptide (QLINTNGSWHINST) 20 µg/mL (JPT-Innovative Peptide Solutions), commercial vaccine against HBV 5 µg/mL (Engerix-B, GlaxoSmithKline) or yeast-derived HBsAg protein 5 µg/mL (Acris Antibodies). Plates were blocked for 2 h with 3 % (w/v) BSA in PBST. Following the blocking and washing, serial diluted mouse sera were added to the wells and incubated for 1 h at RT. Diluted primary mouse AP33 mAb were used as reference. Secondary goat anti-mouse or goat anti-rabbit Abs were used for detection.
Statistical analyses were performed using the SigmaPlot 12.0 software (SYSTAT Software).
T-cell response was analyzed by ELISPOT assay for detection of IFN-γ according to the manufacturer’s instructions (BD Biosciences). Briefly, ELISPOT 96-well plates were coated with purified anti-mouse IFN-γ antibody and blocked using RPMI Medium 1640 (Thermo Fisher Scientific) supplemented with 10 % fetal bovine serum, 100 μg/mL penicillin, and 2 mM l-glutamine. Splenocytes were isolated from the mice 42 days after immunization by passage through 70 μm strainers followed by treatment with ACK lysing buffer (Thermo Fisher Scientific). After washing, splenocytes were seeded at 5 × 105 cells/well and stimulated overnight at 37 °C with overlapping peptides (JPT-Innovative Peptide Solutions) pooled into 3 groups spanning the sHBsAg amino acid sequence at the concentration of 20 μg/mL. Concanavalin A was used as positive control. The mean number of spots from duplicate wells were calculated for each animal and adjusted to represent the mean number of spots per 106 splenocytes.
Electron microscopy and immunogold labeling
For visualization of the particles, the Optiprep gradient fractions were diluted 1:5 in PBS and deposited on formvar-carbon coated 200 mesh nickel grids. Negative staining was performed using 2 % uranyl acetate. Following the staining, samples were analyzed using transmission electron microscope (University of Gdańsk, Poland). For immunogold labeling, grid-deposited 412–425_sHBsAg particles were fixed using 0.1 % (v/v) glutaraldehyde in 4 % paraformaldehyde. Next, the grids were layered on top of AP33 antibodies diluted 1:20 in incubation buffer [PBS buffer, 0.1 % (v/v) BSA-c], and incubated at 4 °C for 16 h. After incubation with primary antibodies, the grids were washed six times using incubation buffer for 5 min at RT. Labeling was performed with goat anti-mouse IgG conjugated with 6 nm gold particles (Aurion), diluted 1:40 in incubation buffer and left for 1 h at RT. After the washing step, the grids were stained with uranyl acetate, dried and analyzed using transmission electron microscope JEM 1200 EX (JEOL Co., Japan) at the Nencki Institute (Warszawa, Poland).
AC, KG designed and performed the experiments, analyzed and interpreted the data, and wrote the manuscript. JT helped in data analysis and revision of the manuscript. GPS carried out the animal vaccination. BG helped in particle purification. KBS revised the manuscript. KG conceived the study, acquired the funding and supervised the research. All authors have read and approved the final manuscript.
We would like to thank Arvind Patel for providing the AP33 antibody and Jonathan Ball for providing the plasmids coding for E1E2 complex from different HCV genotypes. We are also grateful to Michał Rychłowski for his assistance in confocal analysis, Magdalena Narajczyk (Laboratory of Electron Microscopy, Faculty of Biology, University of Gdańsk) for TEM analysis, and Binay Chaubey and Paweł Majewski for critical reading of the manuscript. This study was founded by the Polish National Centre for Research and Development, Grant no. LIDER/12/151/L-3/11/NCBR/2012, and The Polish National Science Centre, Grant no. 2012/05/D/NZ6/00885.
KG and AC are authors of the Polish patent application no P.410950 filed on 01/15/2015. Patent applications do not alter the authors’ adherence to all Microbial Cell Factories polices on sharing data and materials. The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- ION-1 Investigators. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. N Engl J Med. 2014. doi:10.1056/nejmoa1402454.Google Scholar
- Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern. 2015. doi:10.7326/M14-1336.Google Scholar
- Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000. doi:10.1016/s0140-6736(99)06527-7.Google Scholar
- Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol. 2007. doi:10.3748/wjg.v13.i17.2406.Google Scholar
- Schmidt J, Blum H, Thimme R. T-cell responses in hepatitis B and C virus infection: similarities and differences. Emerg Microbes Infect. 2013. doi:10.1038/emi.2013.14.Google Scholar
- Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology. 2014. doi:10.1002/hep.27013.Google Scholar
- Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA. 2007. doi:10.1073/pnas.0607026104.Google Scholar
- Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 2010. doi:10.1016/j.vaccine.2010.06.084.Google Scholar
- Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One. 2013. doi:10.1371/journal.pone.0059776.Google Scholar
- Lange M, Fiedler M, Bankwitz D, Osburn W, Viazov S, Brovko O, et al. Hepatitis C virus hypervariable region 1 variants presented on hepatitis B Virus capsid-like particles induce cross-neutralizing antibodies. PLoS One. 2014. doi:10.1371/journal.pone.0102235.Google Scholar
- Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol. 2005. doi:10.1128/jvi.79.17.11095-11104.2005.Google Scholar
- Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, et al. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology. 2015. doi:10.1002/hep.28428.Google Scholar
- Cheong W, Drummer H, Netter H. Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix. J Virol Methods. 2009. doi:10.1016/j.jviromet.2009.01.015.Google Scholar
- Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide Vaccine: progress and Challenges. Vaccines. 2014. doi:10.3390/vaccines2030515.Google Scholar
- Sandomenico A, Leonardi A, Berisio R, Sanguigno L, Focà G, Focà A, et al. Generation and characterization of monoclonal antibodies against a cyclic variant of Hepatitis C Virus E2 epitope 412-422. J Virol. 2016. doi:10.1128/JVI.02397-15.Google Scholar
- Gavilanes F, Gonzalez-Ros J, Peterson D. Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins. J Biol Chem. 1982;257(13):7770–7.Google Scholar
- Bruss V, Gerhardt E, Vieluf K, Wunderlich G. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology. 1996. doi:10.1159/000150471.Google Scholar
- Kotiw M, Johnson M, Pandey M, Fry S, Hazell SL, Netter HJ, et al. Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing helicobacter pylori KatA epitopes in a Murine H. pylori challenge model. Clin Vaccine Immunol. 2012. doi:10.1128/CVI.05295-11.Google Scholar
- Patient R, Hourioux C, Vaudin P, Pagès JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. N Biotechnol. 2009. doi:10.1016/j.nbt.2009.01.001.Google Scholar
- Cheong WS, Reiseger J, Turner SJ, Boyd R, Netter HJ. Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope. Antiviral Res. 2009. doi:10.1016/j.antiviral.2008.10.003.Google Scholar
- Delpeyroux F, Chenciner N, Lim A, Malpièce Y, Blondel B, Crainic R, et al. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science. 1986. doi:10.1126/science.2425433.Google Scholar
- Berkower I, Raymond M, Muller J, Spadaccini A, Aberdeen A. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. Virology. 2004. doi:10.1016/j.virol.2003.12.017.Google Scholar
- Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol. 2001. doi:10.1128/jvi.75.5.2130-2141.2001.Google Scholar
- Vietheer PT, Boo I, Drummer HE, Netter HJ. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir Ther. 2007;12:477–87.Google Scholar
- Von Brunn A, Früh K, Müller H, Zentgraf HW, Bujard H. Epitopes of the human malaria parasite P. falciparum carried on the surface of HBsAg particles elicit an immune response against the parasite. Vaccine. 1991. doi:10.1016/0264410x(91)90032-2.Google Scholar
- Breitling R, Klingner S, Callewaert N, Pietrucha R, Geyer A, Ehrlich G, et al. Non-pathogenic trypanosomatid protozoa as a platform for protein research and production. Protein Expr Purif. 2002. doi:10.1016/s1046-5928(02)00001-3.Google Scholar
- Gazdag EM, Cirstea IC, Breitling R, Lukeš J, Blankenfeldt W, Alexandrov K. Purification and crystallization of human Cu/Zn superoxide dismutase recombinantly produced in the protozoan Leishmania tarentolae. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010. doi:10.1107/S1744309110019330.Google Scholar
- Potter JA, Owsianka AM, Jeffery N, Matthews DJ, Keck ZY, Lau P, et al. Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol. 2012. doi:10.1128/JVI.02052-12.Google Scholar
- Lünsdorf H, Gurramkonda C, Adnan A, Khanna N, Rinas U. Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the Hepatitis B surface antigen. Microb Cell Fact. 2011. doi:10.1186/1475-2859-10-48.Google Scholar
- Costa C, Delgado I, da Costa J, de Carvalho RF, Mouta Sda S, Jr Vianna CO, et al. Establishment and validation of an ELISA for the quantitation of HBsAg in recombinant hepatitis B vaccines. J Virol Methods. 2011. doi:10.1016/j.jviromet.2010.12.010.Google Scholar
- Wang Y, Keck Z, Foung S. Neutralizing Antibody Response to Hepatitis C Virus. Viruses. 2011. doi:10.3390/v3112127.Google Scholar
- Ball J, Tarr A, McKeating J. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res. 2014. doi:10.1016/j.antiviral.2014.02.013.Google Scholar
- Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol. 2010. doi:10.1128/jvi.02200-09.Google Scholar
- Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med. 2007. doi:10.1038/nm1698.Google Scholar
- Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci USA. 2007. doi:10.1073/pnas.0705522104.Google Scholar
- Wong JA, Bhat R, Hockman D, Logan M, Chen C, Levin A, et al. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol. 2014. doi:10.1128/jvi.01911-14.Google Scholar
- Diminsky D, Schirmbeck R, Reimann J, Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine. 1997. doi:10.1016/s0264-410x(96)00239-3.Google Scholar
- Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines. 2010. doi:10.1586/erv.10.115.Google Scholar
- Kang C, Bishop D, Seo J, Matsuura Y, Choe M. Secretion of particles of hepatitis B surface antigen from insect cells using a baculovirus vector. J Gen Virol. 1987. doi:10.1099/0022-1317-68-10-2607.Google Scholar
- Charnay P, Gervais M, Louise A, Galibert F, Tiollais P. Biosynthesis of hepatitis B virus surface antigen in Escherichia coli. Nature. 1980. doi:10.1038/286893a0.Google Scholar
- Liu R, Lin Q, Sun Y, Lu X, Qiu Y, Li Y, et al. Expression, purification, and characterization of hepatitis B virus surface antigens (HBsAg) in yeast pichia pastoris. Appl Biochem Biotechnol. 2009. doi:10.1007/s12010-009-8527-x.Google Scholar
- Valenzuela P, Medina A, Rutter W, Ammerer G, Hall B. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982. doi:10.1038/298347a0.Google Scholar
- Hamsa P, Chattoo B. Cloning and growth-regulated expression of the gene encoding the hepatitis B virus middle surface antigen in Yarrowia lipolytica. Gene. 1994. doi:10.1016/0378-1119(94)90092-2.Google Scholar
- Patzer EJ, Nakamura GR, Yaffe A. Intracellular transport and secretion of hepatitis B surface antigen in mammalian cells. J Virol. 1984;51(2):346–53.Google Scholar
- Bolhassani A, Shirbaghaee Z, Agi E, Davoudi N. VLP production in Leishmania tarentolae: a novel expression system for purification and assembly of HPV16 L1. Protein Expr Purif. 2015. doi:10.1016/j.pep.2015.08.024.Google Scholar
- Klatt S, Rohe M, Alagesan K, Kolarich D, Konthur Z, Hartl D. Production of glycosylated soluble amyloid precursor protein alpha (sAPPalpha) in Leishmania tarentolae. J Proteome Res. 2013. doi:10.1021/pr300693f.Google Scholar
- Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, Wilson IA, et al. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci USA. 2012. doi:10.1073/pnas.1202924109.Google Scholar
- Li Y, Pierce BG, Wang Q, Keck ZY, Fuerst TR, Foung S, et al. Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem. 2015. doi:10.1074/jbc.m115.643528.Google Scholar
- De Vries RP, Smit CH, de Bruin E, et al. Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. J Virol. 2012. doi:10.1128/JVI.01084-12.Google Scholar
- Beaumont E, Roingeard P. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine. Vaccine. 2015. doi:10.1016/j.vaccine.2015.01.007.Google Scholar
- Netter HJ, Woo WP, Tindle R, Macfarlan RI, Gowans EJ. Immunogenicity of recombinant HBsAg/HCV particles in mice pre-immunised with hepatitis B virus-specific vaccine. Vaccine. 2003. doi:10.1016/S0264-410X(03)00182-8.Google Scholar
- Lee I, Kim C, Ryu W. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles. J Med Virol. 1996. doi:10.1002/(sici)1096-9071(199610)50:2<145:aid-jmv7>3.0.co;2-a.Google Scholar
- Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology. 2013. doi:10.1002/hep.26132.Google Scholar
- Desmond C, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther. 2008;13(2):161–75.Google Scholar
- Comber J, Karabudak A, Shetty V, Testa JS, Huang X, Philip R, et al. MHC class I presented T cell epitopes as potential antigens for therapeutic vaccine against HBV chronic infection. Hepat Res Treat. 2014. doi:10.1155/2014/860562.Google Scholar
- Verstrepen BE, Verschoor EJ, Fagrouch ZC, Mooij P, de Groot NG, Bontrop RE, et al. Strong vaccine-induced CD8 T-Cell responses have cytolytic function in a chimpanzee clearing HCV infection. PLoS One. 2014. doi:10.1371/journal.pone.0095103.Google Scholar
- Al-Barwani F, Young SL, Baird MA, Larsen DS, Ward VK. Mannosylation of virus-like particles enhances internalization by antigen presenting cells. PLoS One. 2014. doi:10.1371/journal.pone.0104523.Google Scholar
- Mishra H, Mishra D, Mishra PK, Nahar M, Dubey V, Jain NK. Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. J Pharm Pharmaceut Sci. 2010;13(4):495–509.Google Scholar
- Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm Res. 2011. doi:10.1007/s11095-011-0459-9.Google Scholar
- Poland G, Jacobson R. Prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med. 2004;351(27):2832–8.View ArticleGoogle Scholar
- Cooreman M, Leroux-Roels G, Paulij W. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci. 2001. doi:10.1007/bf02256597.Google Scholar
- Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-Based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012. doi:10.1126/scitranslmed.3003155.Google Scholar
- Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, et al. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol. 2014. doi:10.1128/jvi.03574-13.Google Scholar